Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

The U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for the investigational use of Sarclisa in combination with bortezomib,...

Related Keywords

United States ,American , ,Drug Administration ,European Union ,European Hematology Association ,American Society Of Clinical Oncology ,Priority Review ,Biologics License Application ,Clinical Oncology ,Annual Meeting ,Hematology Association ,Nonproprietary Naming ,Biological Products Guidance ,